83103-21-3

Basic information

• Product Name: N^α-tert-butyloxycarbonyl-N^G-nitroarginylglycine benzyl ester
• Synonyms: N^α-tert-butyloxycarbonyl-N^G-nitroarginylglycine benzyl ester
• CAS NO: 83103-21-3
• Molecular Weight: 466.494
• Mol File: 83103-21-3.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: N^α-tert-butyloxycarbonyl-N^G-nitroarginylglycine benzyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: N^α-tert-butyloxycarbonyl-N^G-nitroarginylglycine benzyl ester(83103-21-3)
• EPA Substance Registry System: N^α-tert-butyloxycarbonyl-N^G-nitroarginylglycine benzyl ester(83103-21-3)

Safety Data

• Hazardous Substances Data: 83103-21-3(Hazardous Substances Data)

Upstream product

• 2188-18-3 Boc-Arg(NO₂)-OH 
• 1738-76-7 glycine benzyl ester p-toluenesulfonic acid salt 
• 1738-68-7 Gly-OBz 
• 63366-76-7 (toluene-4-sulfonylamino)acetic acid benzyl ester 

Downstream Products

• 1148136-92-8 C₃₂H₅₁N₇O₁₀ 
• 1148136-95-1 C₃₄H₅₅N₇O₁₀ 
• 1148136-98-4 C₃₆H₅₉N₇O₁₀ 
• 1148137-03-4 C₃₈H₆₃N₇O₁₀ 
• 1148137-07-8 C₄₀H₆₇N₇O₁₀ 
• 1148137-11-4 C₄₂H₇₁N₇O₁₀ 
• 246516-47-2 Boc-Arg(Nω-NO2)-Gly-Asp(OBn)-Ser(Bn)-OBn 
• 350688-05-0 Boc-Arg(Nω-NO2)-Gly-Asp(OBn)-Val-OBn 
• 93674-99-8 RGDV 
• 906673-81-2 Boc-Arg(Nω-NO2)-Gly-Asp(OBn)-Phe-OBn 
• 110697-46-6 H-Arg-Gly-Asp-Phe-OH 
• 186379-70-4 Arg(NO₂)-Gly-Asp(OBzl)-OBzl 
• 1223438-41-2 C₄₂H₆₃N₇O₉ 
• 1223438-39-8 C₄₀H₅₉N₇O₉ 

Relevant articles and documents

RGDV-modified gemcitabine: A nano-medicine capable of prolonging half-life, overcoming resistance and eliminating bone marrow toxicity of gemcitabine

Background: Gemcitabine has been widely used as a chemotherapeutic drug. However, drug resistance, short half-life and side effects seriously decrease its chemotherapeutic efficacy. Purpose: The object of preparing RGDV-gemcitabine was to prolong the half

IQCA-TASS: a nano-scaled P-selectin inhibitor capable of targeting thrombus and releasing IQCA/TARGD(S)S in vivo

Thrombosis is a serious threat to human health worldwide. Tetrahydroisoquinoline-3-carboxylic acid (IQCA) is an antithrombotic agent, while Thr-Ala-Arg-Gly-Asp(Ser)-Ser (TASS) can target thrombus. Herein, tetrahydro-isoquinoline-3-carbonyl-Thr-Ala-Arg-Gly-Asp(Ser)-Ser (IQCA-TASS) was designed with the aim towards the discovery of a nano-delivery system for targeting thrombus. In vitro, IQCA-TASS acted on P-selectin and down-regulated P-selectin expression. The IC50 values of IQCA-TASS against the platelet aggregation induced by four aggregators were less than 0.45 nM. In vivo, IQCA-TASS targeted thrombus, released IQCA and TASS inside the thrombus, showed dose-dependent anti-thrombotic action, of which the minimal effective dose was 1 nmol kg-1, and showed anti-inflammatory action. Even with the dose up to 1 μmol kg-1, a dose of 1000 times the minimal effective dose, IQCA-TASS still induced no toxic reaction. In rat plasma, IQCA-TASS formed nanoparticles with diameters of less than 41 nm. The interactions of the nanoparticles with both resting and activated platelets were imaged. IQCA-TASS should be a safe nano-medicine capable of targeting thrombus and releasing anti-thrombotic/anti-inflammatory pharmacophores in disease sites.

RGD-fatty alcohol-modified docetaxel liposomes improve tumor selectivity in vivo

The tripeptide arginine-glycine-aspartate (RGD) was conjugated with various fatty alcohols to obtain RGDOCnH2n + 1 (n = 8, 10, 12, 14, 16, 18), which were incorporated into the bilayer of docetaxel liposomes to improve their tumor sp